Conexeu Sciences has debuted on the Nasdaq with a proposal that aims to change the rules of the game in reconstructive surgery. Its technology develops regenerative matrices that the body reabsorbs, allowing damaged tissues to be repaired, such as breasts after a mastectomy. This offers an alternative to permanent implants, with the promise of improving the quality of life for patients with tissue loss.
How the matrix that the body eliminates on its own works 🧬
Conexeu's technology is based on an extracellular matrix designed to guide natural regeneration. When placed in the damaged area, it acts as a temporary scaffold. The patient's cells migrate into it, rebuilding the lost tissue. Over time, the matrix degrades and is absorbed by the body without leaving a trace. This avoids complications associated with permanent materials, such as rejections or ruptures. The company has already conducted tests in animals and plans clinical trials in humans.
Goodbye to implants, hello to spare flesh 🔄
If all goes well, within a few years we could ask the body to regenerate a breast like ordering a replacement part. Of course, we'll have to see if it can also regenerate the patience required to wait for clinical trials. In the meantime, silicone implants can rest easy: their retirement is not imminent. But watch out, if the matrix works, plastic surgeons will have to update their catalogs.